Step1:CleavageinSolution
- MakefreshcoldDialysisBuffer
WhenmakingfreshcoldDialysisBuffer,pleasebeawarethat:
a)Thetargetproteinneedstobesolubleinthebuffer
b)ThebuffershouldNOTcontainproteaseinhibitor
c)TheDialysisBuffershouldbecompatIBLewithdownstreampurificationprocesses,e.g.minimalamountofEDTAorDTTifNicolumnwillbeusedtoremovethecleavedHis-tag. HereisanexampleofDialysisBuffer.25mMTris-HCl,pH8.0,150-500mMNaCl,14mMb-mercaptoethanol.TurboTEVhasthesameactivityin150mMNaClor500mMNaCland400mMimidazole.
- Dilutethetargetproteinpool
i.Dilutethetargetproteinpoolto1-2mg/mlwithDialysisBuffer.
Note:ThisisoptionalincasethetargetproteinaggregatesinDialysisBuffer.
ii.SaveasmallaliquotasUncutsampleforanalysis.EDTAmaybeaddedto0.5mMfinalconcentrationifthetargetproteinpooliselutedfromNicolumnandEDTAiscompatiblewiththetargetprotein.
- AddTurboTEVProtease
i.AddTurboTEVProteaseataProtease:targetproteinratioof1:100(w/w)or10,000unit(1mg)TurboTEVProteaseto100mgoftargetprotein.
Note:
Thereisnoneedtocalculatethemolarratio.
TurboTEVProteasecanbeaddeddirectlytothetargetprotein.
ItisnotrequiredtochangebufferordiluteTurboTEVProtease.
Theoptimalratioshouldbedeterminedbytheuser;howeveraProtease-to-targetproteinratio(w/w)of1:50to1:200shouldworkformosttargetproteins.
- Dialysis
i.DialyzeagainsttheDialysisBufferat4oCovernight(about16hrs).ThisstepistoremoveimidazoleorglutathioneifNiorglutathionecolumnisusedtoremovethecleavedtagorTurboTEVProteaseaftercleavage.
Ifdesired,thetargetproteinpoolcanbebufferexchangedfirstbeforeTurboTEVcleavage.
Step2:RemovalofTurboTEVProtease
- Applytocolumns
ThedialyzedtargetproteinandTurboTEVProteasemixturecanbeapplieddirectlytoaffinitycolumnsifcompatibleDialysisBufferisused.
ForHis-taggedprotein,useIMACtoremovethecleavedHis-tagandTurboTEVProtease.
ForGST-taggedprotein,useglutathionecolumntoremovethecleavedGST-tagandTurboTEVProtease.
- Optional:SDS-PAGEanalysis
Ifdesired,analyzesamplesusingSDS-PAGEanalysis.ThedifferencebetweenthetaggedandcleavedtargetproteinmaybetoosmalltodetectbySDS-PAGE.ThecleavedHis-tagsometimescanbeseenatthebottomofthegel.
Hyeok-JinKo,EunhyePark,JosephSong,TaekHoYang,HeeJongLee,KyoungHeonKim,andIn-GeolChoi.:FunctionalCellSurfaceDisplayandControlledSecretionofDiverseAgarolyticEnzymesbyEscherichiacoliwithaNovelLigation-IndependentCloningVectorBasedontheAutotransporterYfaL.Appl.Envir.Microbiol.,May2012;78:3051-3058.
JussiJ.Joensuu,AndrewJ.Conley,MichaelLienemann,JimE.Brandle,MarkusB.Linder,andRimaMenassa.:HydrophobinFusionsforHigh-LevelTransientProteinExpressionandPurificationinNicotianabenthamiana.PlantPhysiology,Feb2010;152:622-633.
Neef,Jolandaetal.“VersatileVectorSuitefortheExtracytoplasmicProductionandPurificationofHeterologousHis-TaggedProteinsinLactococcusLactis.”AppliedMicroBIOLOGyandBiotechnology99.21(2015):9037–9048.PMC.Web.9Aug.2017. YoshiyukiTakatsuji,TetsuyaHaruyama,EmmaMaster,MaijaTenkanen,andMarkusB.Linder.Structure-FunctionRelationshipsinHydrophobins:ProbingtheRoleofChargedSideChains.ApplEnvironMicrobiol.Sep2013;79(18):5533-5538.
AdamBShapiro,NingGao,NicholeO¿Connell,JunHu,JasonThresher,Rong-FangGu,RossOverman,IanMHardernandGrahamGSproat.QuantitativeinvestigationoftheaffinityofhumanrespiratorysyncytialvirusphosphoproteinC-terminusbindingtonucleocapsidprotein.VirologyJournal2014,11:191
AlysM.CheatleJarvela,LisaBrubaker,AnastasiaVedenko,AnishaGupta,BruceA.Armitage,MarthaL.Nulyk,andVeroncaF.Hinman.ModularEvolutionofDNA-BindingPreferenceofaTbrainTranscriptionFactorProvidesaMechanismforModifyingGeneRegulatoryNetworks.MolBiolEvol(2014)31(10):2672-2688.
JolandaNeef,FinJ.Milder,DannyG.A.M.Koedijk,MarindyKlaassens,ErikC.Heezius,JosA.H.vanStrijp,AndreasOtto,DorteBecher,JanMaartenvanDijl,GirbeBuist.VersatilevectorsuitefortheextracytoplasmicproductionandpurificationofheterologousHis-taggedproteinsinLactococcuslactis.AppliedMicrobiologyandBiotechnology.Jul2015
MaartenVercruysse,CarolineKohrer,BryanW.Davies,MarkusF.F.Arnold,JohnJ.Mekalanos,UttamL.RajBhandary,GrahamC.Walker.TheHighlyConservedBacterialRNaseYbeYIsEssentialinVibriocholerae,PlayingaCriticalRoleinVirulence,StressRegulation,andRNAProcessing.PLoSPathog.2014Jun;10(6):e1004175.
Yacoby,Iftachetal.“OptimizedExpressionandPurificationforHigh-ActivityPreparationsofAlgal[FeFe]-Hydrogenase.”Ed.PaulD.Riggs.PLoSONE7.4(2012):e35886.PMC.Web.6Oct.2015.
Everest Biotech公司成立于2000年,由英国牛津大学一批生物化学家创建。公司科学家团队具有丰富的抗体纯化及蛋白组学专业知识,雄厚的专业背景赋予了公司能为全球科研人员提供高质量、创新性抗体产品的能力。目前,Everest Biotech可提供3000余种抗体,涉及肿瘤、自身免疫、过敏、心血管疾病、传染病、代谢、神经科学等领域。所有抗体均由Everest Biotech自主研发生产、全部经过肽亲和纯化以保证最佳的特异性和纯度、经过免疫原肽的ELISA和WB实验验证; 由PhD科学家团队提供全方位技术支持服务。Everest Biotech为众多国际知名抗体公司提供OEM服务。